Skip to content
Medical Health Aged Care

Public hearings for the inquiry into diabetes continue

Department of the House of Representatives < 1 mins read

The Health, Aged Care and Sport Committee will hold a public hearing at Parliament House in Canberra for its ongoing inquiry into diabetes this Friday, 16 February 2024.

This hearing will provide an opportunity for the Committee to explore the role of private healthcare, urban planning and development, and the food and grocery industries in diabetes prevention and management. The Committee will also hear from diabetes representative bodies and medical researchers.

The Chair of the Committee, Dr Mike Freelander MP, said: ‘Throughout the inquiry, the Committee has heard about the need to improve the way we prevent and manage diabetes in Australia. This public hearing will explore the cost of diabetes treatments, and ways to improve public awareness of diabetes, obesity and their complications.’

The Deputy Chair of the Committee, Mrs Melissa McIntosh MP, said: ‘The growing impact of diabetes in Australia, including the growing prevalence of the autoimmune disease Type 1 diabetes, means that we must respond to this challenge with forward-thinking policies to deliver better outcomes for diabetes diagnosis, treatment, and management. The Committee looks forward to hearing on Type 1 diabetes healthcare from the Juvenile Diabetes Research Foundation Australia and the Australian Diabetes Society, plus a suite of other organisations at our public hearing.’

The Committee intends to hold further public hearings in March 2024. Details and dates for further public hearings will be available on the Committee’s website as they are announced.

Public hearing

Date: Friday, 16 February 2024
Time: 8.45am – 4.45pm AEDT (Canberra time)
Location: Committee Room 1R3, Parliament House, Canberra

A program for public hearing is available on the inquiry website. A live audio stream of the hearings will also be available on the APH website.

Media inquiries

Dr Mike Freelander MP – Committee Chair
Mike.Freelander.MP@aph.gov.au
(02) 4620 0293

Mrs Melissa McIntosh MP – Committee Deputy Chair
Melissa.McIntosh.MP@aph.gov.au
(02) 4722 0600

For background information

Committee Secretariat
02 6277 4145
Health.Reps@aph.gov.au

More from this category

  • Medical Health Aged Care
  • 31/10/2024
  • 17:55
Kyowa Kirin Co., Ltd.

Kyowa Kirin Announces Changes in Top Leadership Positions to Strengthen Operations as a Global Specialty Pharmaceutical Company

Masashi Miyamoto to be named Chairman and CEO Abdul Mullick to be named President and COO Changes designed to further deliver on company’s 2030…

  • Contains:
  • Medical Health Aged Care
  • 31/10/2024
  • 12:10
MannKind

First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

ICoN-1 study presentation planned November 1 at NTM Symposium AustraliaStudy is cleared by health authorities to proceed in Australia, U.S., Japan and South Korea, with Taiwan anticipated by end of year DANBURY, Conn., Oct. 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it has initiated its first site for its Phase 3 clinical trial evaluating efficacy and safety of Clofazimine Inhalation Suspension for the treatment of nontuberculous mycobacterial (NTM) lung disease. The study,…

  • Business Company News, Medical Health Aged Care
  • 31/10/2024
  • 11:03
Firebrick Pharma

Agreement Signed to Market Nasodine to Healthcare Professionals in Singapore

Firebrick Pharmais pleased to announce that it has executed a Marketing Representation Agreement (the “Agreement”) with Singapore-based, Innorini, trading as Innorini Life Sciences (“Innorini”). The initial term of the Agreement is one year with the option to renew for subsequent one-year terms by mutual agreement. Under the Agreement, Innorini will undertake “Marketing Services” commencing 1 November 2024. The Marketing Services comprise sampling and promotion of Nasodine® Nasal Spray (“Nasodine”) to General Practitioners (“GPs”) and hospital-based doctors and pharmacists (collectively “HCPs”) in Singapore. In addition to building awareness and support of Nasodine by HCPs, Innorini will be expected to sell Nasodine…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.